Evidence map›Paper›PMID 35024538›Full record

ArticleJournal of the Endocrine Society2022

Impact of Thyroglobulin and Thyroglobulin Antibody Assay Performance on the Differential Classification of DTC Patients.

Lise Schoonen, Marjolein Neele, Hans van Toor, Caroline M J van Kinschot, Charlotte van Noord, W Edward Visser, Joost Groen, Lianne S M Boesten, Eef G W M Lentjes, Sjoerd A A van den Berg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Five-year follow-up of Estimabl 2 trail: a critical appraisal.European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lise SchoonenDepartment of Clinical Chemistry, Maasstad Hospital, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4990-1382
Marjolein NeeleDepartment of Clinical Chemistry, Maasstad Hospital, Rotterdam, the Netherlands.
Hans van ToorDepartment of Clinical Chemistry, Erasmus Medical Center, Rotterdam, the Netherlands.
Caroline M J van KinschotDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
Charlotte van NoordDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
W Edward VisserDepartment of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
Joost GroenDepartment of Clinical Chemistry, IJsselland Hospital, Capelle aan de IJssel, the Netherlands.
Lianne S M BoestenDepartment of Clinical Chemistry, IJsselland Hospital, Capelle aan de IJssel, the Netherlands.
Eef G W M LentjesDepartment of Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands.
Sjoerd A A van den BergDepartment of Clinical Chemistry, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-5937-7505
Snjezana KosDepartment of Clinical Chemistry, Maasstad Hospital, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0003-2168-8660
Erasmus MC · NLMaasstad Ziekenhuis · NLIJsselland Ziekenhuis · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextMeasurements of thyroglobulin (Tg) and Tg antibodies are crucial in the follow-up of treated differentiated thyroid cancer (DTC) patients. Interassay differences may significantly impact follow-up.

objectiveThe aim of this multicenter study was to explore the impact of Tg and Tg antibody assay performance on the differential classification of DTC patients, as described in national and international guidelines.

designFour commonly used Tg and Tg antibody assays were technically compared to reflect possible effects on patients with DTC follow-up. Storage stability at different storage temperatures was also investigated for LIAISON® and Kryptor assays, as this is an underexposed topic in current literature.

resultsB.R.A.H.M.S. assays yield approximately 50% lower Tg values over the whole range compared to the DiaSorin and Roche assays investigated. These differences between assays may result in potential misclassification in up to 7% of patients if fixed cutoffs (eg, 1 ng/mL) are applied. Poor correlation was also observed between the Tg antibody assays when the method-specific upper limits of normal are used as cutoffs. Storage of Tg and Tg antibodies was possible for 3 to 4 weeks at -20°C and -80°C. Calibration of the assays, however, was found to be crucial for stable results over time.

conclusionsTechnical aspects of Tg and Tg antibody assays, including interassay differences, calibration and standardization, and cutoff values, may have a significant clinical impact on the follow-up of DTC patients.

Indexed as

differentiated thyroid cancermethod comparisonthyroglobulinthyroglobulin antibodiesthyroid carcinoma

Identifiers

PMID35024538
PMCPMC8739647
OpenAlexW3213037232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.